Design, synthesis, and biological evaluation of thienopyrimidine derivatives as multifunctional agents against Alzheimer's disease

Abstract

A series of 12 S‐substituted tetrahydrobenzothienopyrimidines were designed and synthesized based on the donepezil scaffold. All the newly synthesized compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and the most active compounds were tested for their butyrylcholinesterase (BuChE) inhibitory activity. Moreover, all the synthesized compounds were evaluated for their inhibitory effects against Aβ aggregation and antioxidant activity using the oxygen radical absorbance capacity method. Compounds 4b, 6b, and 8b displayed the most prominent AChE inhibitory action comparable to donepezil. Compound 6b showed the greatest AChE inhibitory action (IC50 = 0.07 ± 0.003 µM) and the most potent BuChE inhibitory action (IC50 = 0.059 ± 0.004 µM). Furthermore, the three compounds exhibited significant antioxidant activity. Compounds 6b and 8b exerted more inhibitory action on Aβ aggregation than donepezil. The cytotoxic activity of compounds 4b, 6b, and 8b against the WI‐38 cell line in comparison with donepezil was examined using 3‐(4,5‐dimethylthiazolyl‐2)‐2,5‐diphenyltetrazolium bromide assay. The results revealed that compounds 6b and 8b were less cytotixic than donepezil, while compound 4b showed nonsignificant cytotoxicity compared to donepezil. For more insights about the binding patterns of the most promising compounds (4b, 6b, and 8b) with the AChE at molecular levels; molecular docking and molecular dynamics simulations were performed. The density functional theory calculations and absorption, distribution, metabolism, excretion and toxicity properties were described as well. The results highlighted compound 6b, which incorporates a phenylpiperazine moiety coupled to a thienopyrimidone scaffold via two‐atom spacer, to be a promising multifunctional therapeutic agent for the treatment of Alzheimer's disease. It is a potent dual AChE and BuChE inhibitor. Furthermore, it had stronger Aβ aggregation inhibitory action than donepezil. Additionally, compound 6b exerted significant antioxidant activity.

Repurposed organoselenium tethered amidic acids as apoptosis inducers in melanoma cancer via P53, BAX, caspases-3, 6, 8, 9, BCL-2, MMP2, and MMP9 modulations

“… 67 Human Caspase-6 (PDB ID: , resolution: 1.82 Å) was extracted from the Protein Data Bank and prepared for docking by correction, energy minimization, and 3D hydrogenation. 68 At the end of the molecular docking process; the best pose for each compound (based on the score and binding interactions) was isolated and visualized to be compared to that of the co-crystallized inhibitor. 69 …”

Major Bioactive Prenylated Flavonoids from Humulus lupulus L., Their Applications in Human Diseases and Structure-Activity Relationships (SAR) – A Review

“…with donepezil have been reported in various recently reported studies. [138][139][140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155] The interactions between the target protein and drug was reported as H bonds with Tyr122, Phe293, Arg294, alkyl bonds with Leu287, Trp284, and pipi stacking with Trp84, and carbon-hydrogen bond with Ser291, Val292, Tyr335. 156 The main interactions for donepezil were reported for H bonds, hydrophobic and pi-interactions with Trp88, Trp279, Phe288, Phe290, Phe330, Tyr334, Arg289.…”

Exploitation of the multitarget role of new ferulic and gallic acid derivatives in oxidative stress-related Alzheimer's disease therapies: design, synthesis and bioevaluation

“…1 ) containing thienopyrimidine as multipotent framework for the AChE (IC 50 = 0.07 μM), BuChE (IC 50 = 0.059 μM) and Aβ 42 (IC 50 = 2.081 μM) with significant antioxidant activity. 31 …”